Andrew S. Feigin, MD Lab Head

Education: MD, Columbia University (1988)
Diplomate of the American Board of Psychiatry and Neurology (1993)

350 Community Drive
Manhasset, NY 11030
Phone: 516-562-2410; Fax: 516-562-2441
afeigin@nshs.edu

Dr. Andrew Feigin’s clinical and research interests focus on Parkinson’s disease (PD) and Huntington’s disease (HD). He uses state-of-the-art imaging methods to develop new therapies for these disorders. Dr. Feigin’s studies utilizing PET imaging have elucidated the mechanisms underlying current therapies for PD, and have led to the use of imaging in studies of novel therapies (e.g. gene therapy for PD).
 
Dr. Feigin is also interested in utilizing imaging as a biomarker for neurodegenerative disorders in the preclinical phase of illness. In a recent study, PET and MRI were utilized to track changes over time in clinically normal subjects who carried the gene mutation for HD.  Similarly, in an ongoing clinical and imaging study, patients with REM Behavior Disorder are being studied to assess whether they are likely to go on to develop a PD.
 
In addition to imaging studies, Dr. Feigin is an investigator for many National Institute of Health and industry sponsored clinical trials of new treatments for PD and HD. Current clinical trials include studies examining the long term effects of nutritional supplements (e.g. creatine, coenzyme Q10) on PD and HD. In addition to his research interests, Dr. Feigin remains a committed and busy clinician caring for patients with PD and related movement disorders.
 

Current Clinical Studies

• A long-term placebo-controlled trial of high dose coenzyme Q10 in patients with mild Parkinson's disease.
• A long-term placebo-controlled trial of high dose coenzyme Q10 in patients with Huntington's disease.
• A long-term placebo-controlled trial of high dose creatine in patients with mild Parkinson's disease.
• A long-term placebo-controlled trial of high dose creatine in patients with Huntington's disease.
• A placebo-controlled trial of a new drug for the movements associated with Huntington's disease.

Current Imaging Studies

“Metabolic Correlates of Pedunculopontine Nucleus Deep Brain Stimulation in Parkinson’s Disease.” - A study funded by the Dana Foundation to examine regional brain changes associated with clinical response to PPN DBS in patients with Parkinson's disease.

“The Molecular Basis for Cognitive Impairment in Parkinson’s Disease: A PET Study.” - A study funded by the Thomas Hartman Foundation to examine brain changes that underlie cognitive impairment in patients with Parkinson's disease.

“Phase 2 Safety and Efficacy Study Evaluating AAV-GAD Gene Transfer to the Subthalamic Nuclei in Subjects with Advanced PD.” - We are the imaging coordination center for this multicenter sham-surgery controlled gene therapy clinical trial for Parkinson's disease.

"REM Behavior Disorder and Parkinsonism: A Longitudinal PET Imaging Study." - An imaging study to assess the relationshp between RBD and Parkinson's disease, and to determine if RBD represents a pre-motor state of Parkinson's disease.

Patients interested in clinical trials can contact Barbara Shannon (516-562-2905) or Jean Ayan (516-562-2426).

		Name:   Barbara Shannon, RN, BSN Position:   Clinical Nurce Coordinator Research:   Barbara Shannon is a clinical nurse coordinator who coordinates clinical trials involving Parkinson's disease and Huntington's disease. Email:   bshannon@nshs.edu
		Name:   Jean Ayan, RN, CEN Position:   Clinical Nurce Coordinator Research:   Jean Ayan is a clinical nurse coordinator who coordinates clinical trials involving Parkinson's disease and Huntington's disease. Email:   jayan@nshs.edu Phone: (516) 562-1514

Selected Publications:

Shane E, Yeh M, Feigin A, Bilezikian JP. Reticulocyte cytosol activator protein: its action upon the beta-adrenergic receptor and the N proteins of adenylate cyclase. J Receptor Research 1984; 4:475-486.

Shane E, Yeh M, Feigin A, Owens J, and Bilezikian JP. Cytosol activator protein from rat reticulocytes requires the stimulatory guanine nucleotide-binding protein for its actions on adenylate cyclase. Endocrinology 1985; 117(1):255-263.

Shane E, Yeh M, Feigin A, Owens J, Bilezikian JP. Reticulocyte cytosol activator protein: effects on the stimulatory and inhibitory regulatory proteins of adenylate cyclase. Endocrinology 1985; 117(1):264-270.

Kieburtz K, Macdonald M, Shih C, Feigin A, Steinberg K, Bordwell K, Zimmerman C, Srinidhi J, Sotack J, Gusella J, and Shoulson I. Trinucleotide repeat length and progression of illness in Huntington’s disease. J Medical Genetics 1994; 31(11):872-874.

Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, and Shoulson I. Functional decline in Huntington’s Disease. Mov Disord 1995; 10(2):211-214.

Feigin A. Restless legs syndrome. JAMA 1995; 274(15):1191-1192.

Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington’s Disease. Mov Disord 1996; 11(3):321-323.

Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre JT, Dunn C, Shoulson I. A controlled trial of remacemide hydrochloride in Huntington’s disease. Mov Disord 1996; 11(3):273-277.

Huntington Study Group (Feigin A, investigator at the University of Rochester Medical Center). Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 1996; 11(2):136-142.

Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsopulos T, Brower CA, Chapieski L, Trinidad K, Como P, Jankovic J. A controlled trial of deprenyl in children with Tourette’s Syndrome and attention deficit hyperactivity disorder. Neurology 1996; 46:965-968.

Kieburtz K, Ketonen L, Cox C, Grossman H, Holloway R, Booth H, Hickey C, Feigin A, Caine E. Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection. Arch Neurol 1996; 53:155-158.

Eidelberg D, Moeller JR, Antonini A, Kazumata K, Dhawan V, Budman C, Feigin A. The metabolic anatomy of Tourette Syndrome. Neurology 1997; 48:927-934.Huntington Study Group (Feigin A, investigator at the University of Rochester Medical Center). Safety and tolerability of the free-radical scavenger OPC-14117 in

Huntington’s Disease.  Neurology 1998; 50(5):1366-1373.

Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, Eidelberg D. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 1998; 13(2):268-274.

Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]-CIT. Mov Disord 1999; 14(3):436-442.

Parkinson Study Group (Feigin A, investigator at North Shore University Hospital). A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD.  Neurology 2000; 54:1583-1588.

Parkinson Study Group (Feigin A, investigator at North Shore University Hospital). A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55:1540-1547.

Parkinson Study Group (Feigin A, investigator at North Shore University Hospital). A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease.  Neurology 2001; 56:455-462.

Feigin A, Fukuda M, Mentis M, Dhawan V, Przyborski S, Moeller JR, Eidelberg D. Metabolic correlates of levodopa response in Parkinson’s disease. Neurology 2001; 57:2083-2088.

Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, Antonini A, Eidelberg D.  Metabolic network abnormalities in early Huntington’s disease: an [18F] fluorodeoxyglucose PET study. J Nucl Med 2001; 42:1591-1595.

Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S, Freed C, Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002; 52:628-634.

Feigin A, Ghilardi MF, Fukuda M, Mentis MJ, Dhawan V, Hacking A, Ghez C, Eidelberg D. Effects of levodopa infusion on motor activation responses in Parkinson’s disease. Neurology, 2002; 59:220-226.

Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, Mentis MJ, Moeller JR, Eidelberg D. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002; 17(6):1265-1270.

Mentis MJ, McIntosh AR, Feigin A, Perrine K, Dhawan V, Mattis P, Edwards C, Spetsieris P, Ma Y, Fukuda M, Eidelberg D. Relationships between the metabolic patterns that correlated with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am  J Psychiatry, 2002; 159(5): 746-754.

Fukuda M, Ghilardi MF, Carbon M, Dhawan V, Ma Y, Feigin A, Mentis MJ, Ghez C, Eidelberg D. Pallidal stimulation for Parkinsonism: improved brain activation during sequence learning. Ann Neurol 2002; 52:144-152.

Feigin A. Nondopaminergic symptomatic therapies for Parkinson’s disease: turn on or turn off? Neurology 2003; 61(3):286-287.

Carbon M, Ghilardi MF, Feigin A, Fukuda M, Nakamura T, Dhawan V, Mentis MJ,  Ghez C, Moeller JR, Eidelberg D. Learning networks in health and Parkinson’s disease: Reproducibility and treatment effects. Hum Brain Mapp, 2003; 19(3): 197-211.

Parkinson Study Group (Feigin A, investigator at North Shore University Hospital). A controlled trial of rasagiline in early Parkinson disease: The TEMPO study.  Arch Neurol 2003; 59:1937-1943.

Feigin A, Ghilardi MF, Carbon M, Edwards C, Fukuda M, Dhawan V, Margouleff C, Ghez C, Eidelberg D. Effects of levodopa on motor sequence learning in Parkinson’s disease. Neurology 2003; 60:1744-1749.

Mentis MJ, Dhawan V, Nakamura T, Ghilardi MF, Feigin A, Edwards C, Ghez C, Eidelberg D. Enhancement of brain activation during trial-and-error sequence learning in early PD. Neurology 2003; 60:612-619.

Mentis MJ, Dhawan V, Feigin A, Delalot D, Zgaljardic D, Edwards C, Eidelberg D. Early stage Parkinson’s disease patients and normal volunteers: comparative mechanisms of sequence learning. Hum Brain Mapp, 2003; 20(4):246-258.

Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43(4):663-670.

Rosas HD, Feigin A, Hersch SM. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx. 2004; 1(2):263-72.

Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A et. al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64:208–215.

Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin A, Eidelberg D. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage, 2005; 26(3):912-21.

Feigin A, Ghilardi MF, Huang C, Carbon-Correll M, Silvestri G, Guttman M, Paulsen JS, Ghez CP, Eidelberg D. Preclinical Huntington’s disease: compensatory brain responses during learning. Annals of Neurology 2006; 59(1):53-59.

Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, et. al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG Neurology 2006; 66: 250 - 252.

Zgaljardic DJ, Borod JC, Foldi NS, Mattis PJ, Gordon MF, Feigin A, Eidelberg D. An Examination of Cognitive and Behavioral Deficits Related to Frontostriatal Circuitry in Nondemented Patients with Parkinson’s disease. Journal of Clinical and Experimental Neuropsychology 2006; 28:1127-1144.

Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D. Network modulation in the treatment of Parkinson’s disease. Brain 2006; 129:2667-2678.

Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain 2007; 130(Pt 11):2858-67.

Kaplitt MG, Feigin A (Shared first author), Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. Safety and Tolerability of AAV-GAD Gene Therapy for Parkinson’s Disease: An open label, phase I trial. Lancet 2007; 369(9579):2097-105.

Ghilardi MF, Feigin A, Battaglia F, Silvestri G, Mattis P, Eidelberg D, Di Rocco A. L-Dopa infusion does not improve explicit sequence learning in Parkinson’s disease. Parkinsonism and Related Disorders 2007; 13:146-151.

Parkinson Study Group (Feigin A, investigator at North Shore University Hospital).  Pramipexole in levodopa-treated Parkinson’s disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacology 2007; 30(2):72-85.

Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson’s disease. Brain 2007; 130(7):1834-46.

Zgaljardic DJ, Borod JC, Foldi NS, Rocco M, Mattis PJ, Gordon MF, Feigin A, Eidelberg D. Relationship Between Self-reported Apathy and Executive Dysfunction in Nondemented Patients With Parkinson Disease. Cog Behav Neurol 2007; 20:184–192.

Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, and Eidelberg D. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson’s disease. Proc Nat Acad Sci 2007; 104(49):19559-19564.

Carbon M, Feigin A, Eidelberg D. Multivariate analysis: Application to the study of hereditary movement disorders. Clinical Neuroscience Research 2007; 6(6):375-380.

Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, Carbon M, Eidelberg D. Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson’s Disease.  J Neuroscience 2008, 28(16):4201-4209.

Argyelan M, Carbon M, Ghilardi MF, Feigin A, Mattis P, Tang C, Dhawan V, Eidelberg D. Dopaminergic suppression of brain deactivation responses during sequence learning. J Neuroscience 2008; 28(42):10687-95.

Brocklebank D, Gayán J, Andresen JM, Roberts SA, Young AB, Snodgrass SR, Penney JB, Ramos-Arroyo MA, Cha JJ, Rosas HD, Hersch SM, Feigin A, Cherny SS, Wexler NS, Housman DE, Cardon LR; The International Venezuela Collaborative Research Group. Repeat instability in the 27-39 CAG range of the HD gene in

the Venezuelan kindreds: Counseling implications. Am J Med Genet B Neuropsychiatr Genet 2008; epub ahead of print.

Ghilardi MF, Silvestri G, Feigin A, Mattis P, Zgaljardic D, Moisello C, Crupi D, Marinelli L, Dirocco A, Eidelberg D.  Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease. Parkinsonism Relat Disord 2008; 14(6):457-64.

Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, Feigin A, Eidelberg D  Abnormal metabolic networks in atypical parkinsonism.. Mov Disord. 2008; 15;23(5):727-33.